Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 202 participants.
Also called NCT03948867
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 202 participants
- Registry
-
NCT03948867
-
- Other papers using this trial's data
- Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Tanzania
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03948867. Non-randomized; no masking; primary purpose treatment. Start 2019-04-24 (actual); primary completion 2022-09-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)
- Condition
- Sickle Cell Anemia in Children
- Intervention (Drug)
- Hydroxyurea
- Intervention (Diagnostic test)
- Elevated Arm TCD Examination
- Intervention (Diagnostic test)
- Normal Arm TCD Examination
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Collaborator
- Bugando Medical Centre
- Collaborator
- The American Society of Hematology
Record details
- Record id
cardio:ct-nct03948867- Content hash
fcce1fbcf3741d2f629174fa3aceff5c293912f093c84f9b954da5238b389be4